This article explores challenges for and the development of civil society engagement and stakeholder representation, transparency, and accountability measures in the European Union, with a specific focus on health policy. The stance of the European Union on stakeholder participation within reform debates of the World Health Organization (WHO) is also considered, along with EU lessons for multi-stakeholders at the WHO. The European Commission has developed a number of measures for stakeholder engagement and transparency; however, the European Union has been prone to lobbying interests and has found difficulty in leading and making accountable the private sector when it comes to achieving its own health policy goals. The strong influence of corporate lobbyists on the European Union has come to light, with concerns about a lack of transparency and accountability in decision-making processes. While the WHO could learn from the European Union in terms of its strategies for stakeholder engagement, it could also heed some of the important lessons for the European Union when it comes to working with a broad range of stakeholders.
Get full access to this article
View all access options for this article.
References
1.
MorlinoL.Democracy and changes: How research tails reality. West Eur. Politics31(1–2):40–59, 2008.
2.
Kohler-KochB., and QuittkatC.What is civil society and who represents civil society in the EU?—Results of an online survey among civil society experts. Policy Society28(1):11–22, 2009.
3.
SmithS., and DalakiouridouE.Contextualising public (e)participation in the governance of the European Union. Eur. J. ePractice7(11), 2009.
4.
JachtenfuchsM., and Kohler-KochB.Governance and Institutional Development. Unpublished paper. Nashville, TN, 2003.
5.
Kohler-KochB.Civil society and EU democracy: ‘Astroturf’ representation?J. Eur. Public Policy17(1):100–116, 2010.
6.
RiekmannS. P.The cocoon of power: Democratic implications of interinstitutional agreements. Eur. Law J.13(1):4–19, 2007.
7.
BroscheidA., and CoenD.Lobbying activity and fora creation in the EU: Empirically exploring the nature of the policy good. J. Eur. Public Policy14(3):346–365, 2007.
8.
CoenD.The evolution of the large firm as a political actor in the European Union. J. of Eur. Public Policy4(1):91–108, 1997.
9.
CoenD.Empirical and theoretical studies in EU lobbying. J. of Eur. Public Policy14(3):333–345, 2007.
10.
SabatierP. A.The advocacy coalition framework: Revisions and relevance for Europe. J. Eur. Public Policy5(1):98–130, 1998.
11.
Corporate Europe Observatory. New EU Staff Regulations Adopted: Small Steps on Revolving Door, Giant Leaps Still Needed. July 4, 2013.
12.
LiptonE., and HakimK.Lobbying bonanza as firms try to influence European Union. The New York Times, October 18, 2013.
13.
Kohler-KochB., and FinkeB.The institutional shaping of EU–society relations: A contribution to democracy via participation?J. Civil Society3(3):205–221, 2007.
14.
CoenD., and KatsaitisA.Chameleon pluralism in the EU: An empirical study of the European Commission interest group density and diversity across policy domains. J. Eur. Public Policy20(8):1104–1119, 2013.
European Commission. Together for Health: A Strategic Approach for the EU 2008–2013. White Paper. COM (2007) 630 final.
17.
European Commission. Communication from the Commission: Towards a Reinforced Culture of Consultation and Dialogue: General Principles and Minimum Standards for Consultation of Interested Parties by the Commission.COM (2002) 704.
KaczynskiP. M.The Treaty of Lisbon: A Second Look at the Institutional Innovations. Joint Study: EPC, CEPS, Egmont. September 2010.
20.
The Evaluation Partnership. Evaluation of the European Platform for Action on Diet, Physical Activity and Health.D. G. H. a. C. European Commission, Brussels, 2010.
21.
BattamsS.Keeping the momentum of the UN High-Level Summit on non-communicable diseases. Health Dipl. Monitor3(3), 2012.
22.
StucklerD.Global health philanthropy and institutional relationships: How should conflicts of interest be addressed?PLoS Med8(4):e1001020, 2011. doi:10.1371/journal.pmed.1001020.
23.
NyeJ.Joseph Nye on Global Power Shifts. TED Talk, July 2010.
24.
FrenkJ., and MoonS.Governance challenges in global health. N. Engl. J. Med.368:936–942, 2013.
25.
RavishankarN.Financing of global health: Tracking development assistance for health from 1990 to 2007. Lancet373(9681):2113–2124, 2009.
26.
KickbuschI.Addressing global health governance challenges through a new mechanism: The proposal for a Committee C of the World Health Assembly. J. Law Med. Ethics38(3):550–563, 2010.
27.
SridharD., and GostinL.Reforming the World Health Organization. JAMA Online. March 29, 2011.
28.
FaidM.Multi-Stakeholder Governance in Governance for Global Health – Approaches and Solutions. Unpublished literature review. Global Health Programme, The Graduate Institute for International and Development Studies, 2011.
29.
WillkeH.Smart Governance: Governing the Global Knowledge Society.The University of Chicago Press, Chicago, 2007.
30.
GostinL., and MokE.Grand challenges in global health governance. Br. Med. Bull.90:7–18, 2009.
31.
BuseK., and TanakaS.Global public-private health partnerships: Lessons learned from ten years of experience and evaluation. Int. Dent. J.61(Suppl. 2), 2011.
32.
LeggeD.Future of WHO hangs in the balance. BMJ345(e6877), 2012.
33.
CohenD.WHO and the pandemic flu ‘conspiracies.’BMJ340, June 12, 2010.
34.
SukkarE.WHO Reveals H1N1 Committee's Links with Big Pharma.Global Health Watch, 2010. http://www.ghwatch.org/who-watch/h1n1 (accessed November 4, 2013).
35.
YachD.The role and challenges of the food industry in addressing chronic disease. Global Health6(10):1–8, 2010.
36.
KatzA. R.Noncommunicable diseases: Global health priority or market opportunity? An illustration of the World Health Organization at its worst and at its best. Int. J. Health Serv.43(3):437–458, 2013.
37.
LavalleA.Beyond comparative anecdotalism: Lessons on civil society and participation from Sao Paulo, Brazil. World Dev.33(6):951–964, 2005.
38.
BattamsS.The social determinants of health and civil society engagement in the WHO Reform and beyond: Negotiations at the 65th World Health Assembly. Health Dipl. Monitor3(4), 2012.
39.
LencuchaR.The role of non-governmental organizations in global health diplomacy: Negotiating the Framework Convention on Tobacco Control. Health Policy Plann.1–8, 2010.
40.
DenticoN.In focus: Implementing the WHO global strategy on public health, innovation & IP: An opportunity that should not be squandered by poor implementation. IQ Sensato.3(1):1–8, 2009.
41.
World Health Organization. Governance and Promoting Engagement with Other Stakeholders and Involvement with and Oversight of Partnerships. Report by the Secretariat, EB130/5 Add. 4, 2011. http://apps.who.int/gb/ebwha/pdf_files/EB130/B130_5Add4-en.pdf (accessed November 4, 2013).
42.
BattamsS.The EU's Role in Global Health and the WHO Reform; Between Health and Foreign Policy. Lisboan Erasmus Academic Network Workshop, EU External Representation in International Contexts: Reform Practices After Lisbon. Clingendael Institute, The Hague, 2012.
43.
BattamsS.The European Union's Voice and Influence on Global Health and the Reform of the World Health Organization: The Role of Diplomacy. The European Union in International Affairs 111 Conference, Brussels, 2012.
